COVID Arm After Moderna Booster in Healthcare Worker: A Case Report

Authors

  • Anshari Saifuddin Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Sukamto Koesnoe Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Nia Kurniati Division of Allergy and Clinical Immunology, Department of Child Health, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Sondang Sirait Department of Dermatovenereology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Riesye Arisanty Department of Pathology and Anatomy, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Evy Yunihastuti Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Keywords:

COVID arm, COVID-19, booster, Moderna, vaccination, healthcare worker

Abstract

SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate of COVID-19. Various vaccination platforms are produced, such as inactivated, viral vector, mRNA, and protein subunit. The vaccination booster program with mRNA platform (Moderna) was launched by the Indonesian government to give better protection for health care workers, particularly from delta variant. In this case report, we discuss one of the typical side effects of Moderna vaccine, which is referred to as the COVID arm.

References

Worldometers. Coronavirus cases in world. [cited 2021 August 26]. Available from https://www.worldometers.info/coronavirus/

Kementerian Komunikasi dan Informatika. Sebaran kasus COVID-19 di Indonesia. [cited 2021 August 26]. Available from https://covid19.go.id/

Kementerian Kesehatan RI. Materi Penanganan COVID-19. Kemenkes. Desember 2020.

Tim mitigasi Ikatan Dokter Indonesia. Data kematian dokter di Indonesia akibat COVID-19. IDI. 2021

Lingren AL, Austin AH, Welsh K. COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis. J Primary Care Comm Health. 2021;12:1-5

Allergic Reactions. Centers for Disease Control and Prevention. [cited 2021 August 26]. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html

Baen LR, Sahly E, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-16.

Blumenthal KG, Freeman EF, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2.N Engl J Med. 2021;384:1273-7.

Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130:25-43.

McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141:463-72.

U.S. Food and Drug Administration. Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older [fact sheet]. [cited 2021 August 26]. Available from https://www.fda.gov/ media/144414/download#page=2

U.S. Food and Drug Administration. Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 18 Years of Age and Older [fact sheet].[cited 2021 August 26]. Available from https://www.fda.gov/ media/144638/download#page=2

Allergic Reactions. Centers for Disease Control and Prevention. [cited 2021 August 26]. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic- reaction.html

Fisher AA. Immediate and delayed allergic contact reactions to polyethylene glycol. Contact Dermatitis. 1978;4:135-8.

Halperin S, Kohl KS, Gidudu J, et al. Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5803-20.

Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996;335(8):547-54.

Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141-6.

Downloads

Published

2021-10-04

How to Cite

Saifuddin, A., Koesnoe, S., Kurniati, N., Sirait, S., Arisanty, R., & Yunihastuti, E. (2021). COVID Arm After Moderna Booster in Healthcare Worker: A Case Report. Acta Medica Indonesiana, 53(3), 326. Retrieved from https://actamedindones.org/index.php/ijim/article/view/1906

Issue

Vol. 53 No. 3 (2021): Acta Medica Indonesiana

Section

CASE REPORT

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.